Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 380 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Androgen Suppression Clear all
Completed Not applicable Interventional Results available

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

NCT01542021
View directory record Official record
Conditions
Prostate Cancer, Prostatic Adenocarcinoma
Interventions
degarelix injection, androgen deprivation therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

NCT00129142
View directory record Official record
Conditions
Prostate Cancer, Osteoporosis, Fractures
Interventions
Toremifene Citrate
Drug
Lead sponsor
GTx
Industry
Eligibility
50 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
136
States / cities
Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

NCT01664923
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Bicalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

NCT07210086
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT, ARSI, No ADT/ARSI -decline
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Not applicable Interventional

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

NCT05327465
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
Interventions
Aerobic and resistance exercise, Usual Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

NCT03456843
View directory record Official record
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Not applicable Interventional

An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy

NCT02248350
View directory record Official record
Conditions
Prostate Cancer, Physical Activity, Side-effects
Interventions
Supervised and Home Based Exercise, Stretching Control Group
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 23, 2026, 2:51 PM EDT
Not yet recruiting Phase 2 Interventional

Folate Study in Men With Advanced Prostate Cancer

NCT06536374
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimethoprim Tablets
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study

NCT06064149
View directory record Official record
Conditions
Prostate Cancer
Interventions
CARE-PC Web-Based Application
Behavioral
Lead sponsor
Vivek Narayan
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 23, 2026, 2:51 PM EDT
Terminated No phase listed Observational

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

NCT03718338
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Evaluation, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 23, 2026, 2:51 PM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, Conventional NSAA, LHRHA, External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247
View directory record Official record
Conditions
Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
Drug · Behavioral · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
30 Years to 79 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Terminated Not applicable Interventional Results available

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01428193
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Flutamide, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 23, 2026, 2:51 PM EDT
Withdrawn Phase 2 Interventional

Insulin Resistance and Androgen Deprivation Therapy

NCT04995978
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance
Interventions
Pioglitazone 30 mg, placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

Castrate Resistant Prostate Cancer Enhertu Therapy

NCT06610825
View directory record Official record
Conditions
Prostate Cancer Metastatic, Prostate Cancer, CRPC
Interventions
Enhertu
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

De-implementation of Low Value Castration for Men With Prostate Cancer

NCT03579680
View directory record Official record
Conditions
Cancer of Prostate
Interventions
ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 23, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

NCT01410942
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed No phase listed Observational

Micro RNAs to Predict Response to Androgen Deprivation Therapy

NCT02366494
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

NCT00116779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 23, 2026, 2:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

NCT02946996
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin, OPC
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 23, 2026, 2:51 PM EDT